Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-206390
Filing Date
2026-05-05
Accepted
2026-05-05 16:09:25
Documents
58
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q trvi-20260331.htm   iXBRL 10-Q 1557556
2 EX-10.1 trvi-ex10_1.htm EX-10.1 28834
3 EX-31.1 trvi-ex31_1.htm EX-31.1 18099
4 EX-31.2 trvi-ex31_2.htm EX-31.2 18088
5 EX-32.1 trvi-ex32_1.htm EX-32.1 12329
6 EX-32.2 trvi-ex32_2.htm EX-32.2 12304
7 GRAPHIC img64809683_0.jpg GRAPHIC 41981
  Complete submission text file 0001193125-26-206390.txt   7376721

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT trvi-20260331.xsd EX-101.SCH 932631
62 EXTRACTED XBRL INSTANCE DOCUMENT trvi-20260331_htm.xml XML 1430237
Mailing Address 195 CHURCH STREET 16TH FLOOR NEW HAVEN CT 06510
Business Address 195 CHURCH STREET 16TH FLOOR NEW HAVEN CT 06510 203-304-2499
Trevi Therapeutics, Inc. (Filer) CIK: 0001563880 (see all company filings)

EIN.: 450834299 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38886 | Film No.: 26943135
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)